Going into 2026, biotech company Ladder Bio is embracing a new identity.

G2 Bio Companies has launched with $200 million in financing from Temasek to develop gene therapy candidates out of the University of Pennsylvania. The company is led by Penn gene therapy expert James ...

I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...